Consolidated Statement of Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2023		26,597,000
Stockholders' equity, beginning balance at Dec. 31, 2023	$ 88,103	$ 27	$ 702,969	$ (797)	$ (614,096)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)		53,000
Issuance of common stock from exercises of options and employee stock purchase plan	811		811
Issuance of common stock upon vesting of restricted stock units (in shares)		1,014,000
Net share settlement of restricted stock units (in shares)		(347,000)
Net share settlement of restricted stock units	(7,504)		(7,504)
Stock-based compensation	10,131		10,131
Comprehensive gain (loss), net	173			173
Net loss	(43,936)				(43,936)
Stockholders' equity, ending balance (in shares) at Mar. 31, 2024		27,317,000
Stockholders' equity, ending balance at Mar. 31, 2024	47,778	$ 27	706,407	(624)	(658,032)
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2023		26,597,000
Stockholders' equity, beginning balance at Dec. 31, 2023	88,103	$ 27	702,969	(797)	(614,096)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(123,447)
Stockholders' equity, ending balance (in shares) at Sep. 30, 2024		30,429,000
Stockholders' equity, ending balance at Sep. 30, 2024	84,367	$ 30	821,121	759	(737,543)
Stockholders' equity, beginning balance (in shares) at Mar. 31, 2024		27,317,000
Stockholders' equity, beginning balance at Mar. 31, 2024	47,778	$ 27	706,407	(624)	(658,032)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)		75,000
Issuance of common stock from exercises of options and employee stock purchase plan	1,008		1,008
Issuance of common stock upon vesting of restricted stock units (in shares)		42,000
Stock-based compensation	7,544		7,544
Comprehensive gain (loss), net	209			209
Net loss	(46,660)				(46,660)
Stockholders' equity, ending balance (in shares) at Jun. 30, 2024		27,434,000
Stockholders' equity, ending balance at Jun. 30, 2024	9,879	$ 27	714,959	(415)	(704,692)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)		196,000
Issuance of common stock from exercises of options and employee stock purchase plan	4,099		4,099
Issuance of common stock upon vesting of restricted stock units (in shares)		48,000
Issuance of common stock, net of transaction costs (in shares)		2,751,000
Issuance of common stock, net of transaction costs	93,877	$ 3	93,874
Stock-based compensation	8,189		8,189
Comprehensive gain (loss), net	1,174			1,174
Net loss	(32,851)				(32,851)
Stockholders' equity, ending balance (in shares) at Sep. 30, 2024		30,429,000
Stockholders' equity, ending balance at Sep. 30, 2024	$ 84,367	$ 30	821,121	759	(737,543)
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2024	30,473,000	30,473,000
Stockholders' equity, beginning balance at Dec. 31, 2024	$ 70,868	$ 30	829,860	305	(759,327)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)		44,000
Issuance of common stock from exercises of options and employee stock purchase plan	290		290
Issuance of common stock upon vesting of restricted stock units (in shares)		262,000
Net share settlement of restricted stock units (in shares)		(98,000)
Net share settlement of restricted stock units	(1,451)		(1,451)
Repurchases and retirements of common stock (in shares)		(293,000)
Repurchases and retirements of common stock	(5,383)		(5,383)
Stock-based compensation	9,170		9,170
Comprehensive gain (loss), net	(144)			(144)
Net loss	(39,329)				(39,329)
Stockholders' equity, ending balance (in shares) at Mar. 31, 2025		30,388,000
Stockholders' equity, ending balance at Mar. 31, 2025	$ 34,021	$ 30	832,486	161	(798,656)
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2024	30,473,000	30,473,000
Stockholders' equity, beginning balance at Dec. 31, 2024	$ 70,868	$ 30	829,860	305	(759,327)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (62,846)
Stockholders' equity, ending balance (in shares) at Sep. 30, 2025	27,575,152	27,575,000
Stockholders' equity, ending balance at Sep. 30, 2025	$ (29,416)	$ 28	792,682	47	(822,173)
Stockholders' equity, beginning balance (in shares) at Mar. 31, 2025		30,388,000
Stockholders' equity, beginning balance at Mar. 31, 2025	34,021	$ 30	832,486	161	(798,656)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)		84,000
Issuance of common stock from exercises of options and employee stock purchase plan	1,423		1,423
Issuance of common stock upon vesting of restricted stock units (in shares)		62,000
Repurchases and retirements of common stock (in shares)		(2,561,000)
Repurchases and retirements of common stock	(50,619)	$ (2)	(50,617)
Stock-based compensation	9,239		9,239
Comprehensive gain (loss), net	(167)			(167)
Net loss	(38,630)				(38,630)
Stockholders' equity, ending balance (in shares) at Jun. 30, 2025		27,973,000
Stockholders' equity, ending balance at Jun. 30, 2025	(44,733)	$ 28	792,531	(6)	(837,286)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)		68,000
Issuance of common stock from exercises of options and employee stock purchase plan	788		788
Issuance of common stock upon vesting of restricted stock units (in shares)		24,000
Repurchases and retirements of common stock (in shares)		(490,000)
Repurchases and retirements of common stock	(9,794)		(9,794)
Stock-based compensation	9,157		9,157
Comprehensive gain (loss), net	53			53
Net loss	$ 15,113				15,113
Stockholders' equity, ending balance (in shares) at Sep. 30, 2025	27,575,152	27,575,000
Stockholders' equity, ending balance at Sep. 30, 2025	$ (29,416)	$ 28	$ 792,682	$ 47	$ (822,173)

ANAPTYSBIO, INC 10-Q